Vorapaxar for secondary stroke prevention: perspectives and obstacles
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015
112
Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges
THROMBOSIS AND HAEMOSTASIS, 2015
113
Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30 day mortality in patients with ST-elevated myocardial infarction
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015
114
Survival After Solid Cancers in Antithrombotic Trials
Serebruany VL, 김무현, Tomek A
AMERICAN JOURNAL OF CARDIOLOGY, 2015
115
Flavonoids activate endothelial nitric oxide synthase by altering their phosphorylation via mitogen-activated protein kinase pathways in glucose-induced endothelial cells
김무현, Chae Eun Kim, Sung-Whan Kim, 한성호
journal of fuctional foods, 2015
116
Comparison of prasugrel and ticagrelor antiplatelet effects in Korean patients presenting with ST-segment elevation myocardial infarction
Cai De Jin, 조용락, 박경일, 박종성, 김무현, 박태호, 김영대, Long Zhe Guo, 이영석
Circulation Journal, 2015
117
Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects.
김무현, 곽룡철, 김재덕, 이주영, 이소정, 박민규, 조용락, 박태호
Platelets, 2015
118
The Dual Antiplatelet Therapy Trial after the FDA Update: Noncardiovascular Deaths, Cancer and Optimal Treatment Duration
김무현, Serebruany V.L, Cherepanov V., Golukhova E.Z
CARDIOLOGY, 2015
119
Falsely high B-type natriuretic peptide concentration in patients without heart failure attributed to AxSYM assay: case series of eight subjects
ESC HEART FAILURE, 2015
120
Is heparin an acceptable anticoagulant when glycoprotein IIb/IIIa inhibitors are not used?